Related Experiment Video

Updated: May 21, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy

Lei Zheng1, Elizabeth M Jaffee

  • 1The Sidney Kimmel Comprehensive Cancer Center; Department of Oncology; The Skip Viragh Center for Pancreatic Cancer; Department of Pathology; The Sol Goldman Pancreatic Cancer Center; Baltimore, MD USA ; Department of Surgery; Johns Hopkins University School of Medicine; Baltimore, MD.

Oncoimmunology
|June 22, 2012
PubMed

Insights

Annexin A2 is a newly identified tumor antigen associated with pancreatic cancer. This finding supports its potential as a target for novel immunotherapies against pancreatic cancer.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Pancreatic cancer remains a significant health challenge with limited effective treatments.
  • Tumor antigens are crucial targets for developing immunotherapies.
  • Identifying novel antigens is essential for advancing pancreatic cancer treatment strategies.

Purpose of the Study:

  • To identify and characterize novel tumor antigens in pancreatic cancer.
  • To evaluate the potential of identified antigens as targets for immunotherapy.

Main Methods:

  • Proteomic analysis to identify differentially expressed proteins in pancreatic tumors.
  • Immunohistochemistry and Western blot to validate antigen expression.
  • Functional assays to assess the role of the antigen in cancer progression and metastasis.

Main Results:

  • Annexin A2 was identified as a novel tumor antigen associated with pancreatic cancer.
  • Annexin A2 expression correlates with pancreatic cancer progression and metastasis.
  • Annexin A2 demonstrates potential as a target for therapeutic antibodies and T cell-based immunotherapy.

Conclusions:

  • Annexin A2 is a promising new target for pancreatic cancer immunotherapy.
  • Targeting Annexin A2 may offer a novel therapeutic strategy for patients with pancreatic cancer.
  • Further research into Annexin A2-based therapies is warranted.

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Acute Pancreatitis II: Pathophysiology01:21

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...